We read with interest the paper by Li et al, 1 which identified 27 microRNAs (miRNAs) differentially expressed in plasma from Chinese patients with essential hypertension. These data add to findings for kidneys of differential expression of 24 different miRNAs and 60 mRNAs. 2 Hypertension is now another disease in which miRNAs have been implicated. miRNAs negatively regulate transcript levels by binding to the 3Ј-untranslated region of mRNA and destabilizing it. A polymorphism in an miRNA target site could thus contribute to hypertension. The only example to date in hypertension is the AGT1R A1166C polymorphism targeted by miR-155. 3 Alternatively, dysregulation of miRNA expression, by altering transcript levels, may explain overexpression in kidney of renin and several other mRNAs in hypertension, as confirmed by cotransfection experiments in kidney cells. 2 Although it would be of interest to find blood markers for hypertension and its intermediate phenotypes, high intersubject variability of miRNA levels in the study by Li et al 1 argues against this.
To the Editor:
We read with interest the paper by Li et al, 1 which identified 27 microRNAs (miRNAs) differentially expressed in plasma from Chinese patients with essential hypertension. These data add to findings for kidneys of differential expression of 24 different miRNAs and 60 mRNAs. 2 Hypertension is now another disease in which miRNAs have been implicated. miRNAs negatively regulate transcript levels by binding to the 3Ј-untranslated region of mRNA and destabilizing it. A polymorphism in an miRNA target site could thus contribute to hypertension. The only example to date in hypertension is the AGT1R A1166C polymorphism targeted by miR-155. 3 Alternatively, dysregulation of miRNA expression, by altering transcript levels, may explain overexpression in kidney of renin and several other mRNAs in hypertension, as confirmed by cotransfection experiments in kidney cells. 2 Although it would be of interest to find blood markers for hypertension and its intermediate phenotypes, high intersubject variability of miRNA levels in the study by Li et al 1 argues against this.
Another main finding by Li et al 1 was higher human cytomegalovirus (HCMV) DNA in hypertensive subjects (53%) than in normotensive subjects (31%), as well as higher virus titers (1870 versus 54 copies/mL). They suggest higher HMCV prevalence could be a cause. But it could be a consequence, in that hypertensioninduced pathology could increase susceptibility to HCMV. Despite the strong correlation between virus titers and blood pressure, a primary association with atherosclerosis or other conditions more common in hypertension cannot be discounted. HCMV was not a cause or consequence of hypertension in the 47% of hypertensive subjects not infected with HCMV. Because 31% of normotensive subjects were infected, factors other than HCMV are required for hypertension to develop. In China, 48% of the population is HCMV seropositive. 4 Prevalence in the United States is similar. 5 If HCMV is involved, it is likely 1 among other factors in the 53% of infected hypertensive subjects.
The miRNA that exhibited the biggest difference between hypertensive and normotensive subjects (hcmv-miR-UL112) was encoded by HCMV and was present in circulating endothelial cells. hcmv-miR-UL112, by targeting sites in the 3Ј-untranslated region of interferon regulatory factor 1 and major histocompatibility complex class I polypeptide-related chain B mRNAs, downregulated reporter gene expression. Instead of using, say, human umbilical vein endothelial cells, Li et al performed these assays in HEK293 kidney cells, as we used to confirm our kidney findings. 2 It is therefore apparent that miRNAs have now emerged as important new factors in hypertension etiology. Determination of cause-and-effect relations, the mechanisms that explain any effect on blood pressure, as well as replication in other settings will be necessary before confirming a role for HCMV and hcmv-miR-UL112, as well as other miRNAs, in hypertension etiology. The findings described by Li et al 1 are among the first to take advantage of novel genome-wide expression array platforms that could lead to the discovery of possible roles for miRNAs in hypertension. The importance of these discoveries and the novel insights provided into hypertension etiology should be recognized.
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